Genmab — April 2020

[E_L]

ADCT-301 Ph II seems fully accrued https://clinicaltrials.gov/ct2/history/NCT04052997?A=15&B=16&C=merged#StudyPageTop

[gdn55]

Kan ugen godkendes? Jeg er meget tilfreds, frygtede det værste.

[JKY_VH]

Den er absolut godkendt og god weekend:-)

[Solsen]

Tilfredshed herfra og god weekend

[gentogen]

EL 15.47: I am not so sure. That would be extremely quick. They are including new location in new countries in the trial so perhaps it is just for the time being they are not recruiting?

[E_L]

yes, that is certainly also possible,... i was actually happy that they finished so quick and just in time before corona shut recruitment down, but maybe exactly that happened...

[E_L]

New BMS-986253 trial: Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04347226

[Solsen]

Thanks EL you are a master

[E_L]

haha, fortunately there are enough here to correct all my mistakes

[Solsen]

Well we dont know about ADC-301. You could be right...

[Solsen]

Vi mangler lidt over 3% for at NBI er i ATH

[GeorgeBest]

I 2015 var vi vist højere på NBI...

[Bulder]

Stærkt us-luk. Ikke mindst trukket op af remdesivir-rygterne. Så må vi se om de holder.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Solsen]

Korrekt GB https://finance.yahoo.com/quote/^NBI?p=^NBI

[StockBull]

Remdesivir: science remains equivocal about whether this drug actually works for covid-19 sufferers. Two trials in China have already failed, because of lack of enrolment. (China started its trials relatively late in its epidemic, so it was hard to recruit sufficient numbers of patients.) The recent publication in the New England Journal of Medicine, of a study of remdesivir given to 53 severely afflicted patients, reported that 68% of them improved.

[StockBull]

However the study has proven divisive among scientists. To begin with, errors can be large given the small number of patients. Moreover, the trial was not “randomised”, so there is no way of knowing whether the sample properly reflects the population of severely afflicted patients. Last, there was no comparison group that was given a placebo, ie, a substance with no therapeutic effect, to establish the real effectiveness of the drug.

[StockBull]

For all the excitement it generated, the STAT report was little more than a leaked conversation between doctors. It revolved around a trial at the University of Chicago with 125 patients, mostly severely ill with covid-19. One of the doctors is reported as saying that most of the patients had been discharged and only two had died. But even if this is correct, the lack of a placebo group makes it hard to assess the real worth of the drug. The University of Chicago itself warned that drawing any

[StockBull]

any conclusions was "premature and scientifically unsound".